Comments
Loading...
CRISPR Therapeutics Analyst Ratings and Price Targets | NASDAQ:CRSP | Benzinga
CRISPR Therapeutics Corp has a consensus price target of $567.61 based on the ratings of 38 analysts. The high is $1350 issued by HSBC on May 10, 2024<. The low is $100 issued by Deutsche Bank on August 5, 2024. The 3 most-recent analyst ratings were released by New Street Research, Goldman Sachs, and Deutsche Bank on August 6, 2024, August 5, 2024, and August 5, 2024, respectively. With an average price target of $118.33 between New Street Research, Goldman Sachs, and Deutsche Bank, there's an implied 0.21% upside for CRISPR Therapeutics Corp from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Needham
Citigroup
Morgan Stanley
Evercore ISI Group
Goldman Sachs
1calculated from analyst ratings
Analyst Ratings for CRISPR Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 04/09/2025 | Buy Now | — | Needham | Gil Blum48% | $84 → $84 | Reiterates | Buy → Buy | Get Alert |
| 02/19/2025 | Buy Now | — | Cantor Fitzgerald | Eric Schmidt28% | — | Reiterates | Neutral → Neutral | Get Alert |
| 02/18/2025 | Buy Now | — | Citigroup | Yigal Nochomovitz54% | $89 → $82 | Maintains | Buy | Get Alert |
| 02/14/2025 | Buy Now | — | Morgan Stanley | Terence Flynn65% | $30 → $32 | Maintains | Underweight | Get Alert |
| 02/14/2025 | Buy Now | — | Evercore ISI Group | Liisa Bayko69% | $60 → $99 | Upgrade | In-Line → Outperform | Get Alert |
| 02/13/2025 | Buy Now | — | Goldman Sachs | Salveen Richter52% | $66 → $57 | Maintains | Neutral | Get Alert |
| 02/13/2025 | Buy Now | — | JMP Securities | Silvan Tuerkcan44% | $86 → $86 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 02/13/2025 | Buy Now | — | Stifel | Benjamin Burnett43% | $53 → $49 | Maintains | Hold | Get Alert |
| 02/13/2025 | Buy Now | — | HC Wainwright & Co. | Mitchell Kapoor43% | $65 → $65 | Reiterates | Buy → Buy | Get Alert |
| 02/13/2025 | Buy Now | — | Chardan Capital | Geulah Livshits43% | $94 → $84 | Maintains | Buy | Get Alert |
| 02/12/2025 | Buy Now | — | Truist Securities | Joon Lee75% | $100 → $120 | Maintains | Buy | Get Alert |
| 02/12/2025 | Buy Now | — | RBC Capital | Luca Issi36% | $53 → $48 | Maintains | Sector Perform | Get Alert |
| 02/12/2025 | Buy Now | — | Needham | Gil Blum48% | $84 → $84 | Reiterates | Buy → Buy | Get Alert |
| 02/12/2025 | Buy Now | — | Barclays | Gena Wang49% | $55 → $56 | Maintains | Equal-Weight | Get Alert |
| 02/03/2025 | Buy Now | — | HC Wainwright & Co. | Mitchell Kapoor43% | → $65 | Initiates | → Buy | Get Alert |
| 01/14/2025 | Buy Now | — | Needham | Gil Blum48% | $84 → $84 | Reiterates | Buy → Buy | Get Alert |
| 01/07/2025 | Buy Now | — | B of A Securities | Geoff Meacham60% | $98 → $85 | Maintains | Buy | Get Alert |
| 12/20/2024 | Buy Now | — | JMP Securities | Silvan Tuerkcan44% | $86 → $86 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 12/10/2024 | Buy Now | — | Chardan Capital | Geulah Livshits43% | $94 → $94 | Maintains | Buy | Get Alert |
| 11/06/2024 | Buy Now | — | RBC Capital | Luca Issi36% | $53 → $53 | Reiterates | Sector Perform → Sector Perform | Get Alert |
| 11/06/2024 | Buy Now | — | Barclays | Gena Wang49% | $59 → $55 | Maintains | Equal-Weight | Get Alert |
| 11/06/2024 | Buy Now | — | Needham | Gil Blum48% | $84 → $84 | Reiterates | Buy → Buy | Get Alert |
| 10/04/2024 | Buy Now | — | RBC Capital | Luca Issi36% | $60 → $53 | Maintains | Sector Perform | Get Alert |
| 08/12/2024 | Buy Now | — | Truist Securities | Joon Lee75% | $120 → $100 | Maintains | Buy | Get Alert |
| 08/08/2024 | Buy Now | — | Cantor Fitzgerald | Eric Schmidt28% | — | Reiterates | → Neutral | Get Alert |
| 08/06/2024 | Buy Now | — | Stifel | Benjamin Burnett43% | $60 → $59 | Maintains | Hold | Get Alert |
| 08/06/2024 | Buy Now | — | Barclays | Gena Wang49% | $67 → $59 | Maintains | Equal-Weight | Get Alert |
| 08/06/2024 | Buy Now | — | RBC Capital | Luca Issi36% | $66 → $60 | Maintains | Sector Perform | Get Alert |
| 08/06/2024 | Buy Now | — | Chardan Capital | Geulah Livshits43% | $112 → $94 | Maintains | Buy | Get Alert |
| 08/06/2024 | Buy Now | — | Needham | Gil Blum48% | $88 → $84 | Maintains | Buy | Get Alert |
| 06/28/2024 | Buy Now | — | Guggenheim | Debjit Chattopadhyay48% | — | Assumes | → Neutral | Get Alert |
| 06/27/2024 | Buy Now | — | Needham | Gil Blum48% | $88 → $88 | Reiterates | Buy → Buy | Get Alert |
| 06/17/2024 | Buy Now | — | Piper Sandler | Edward Tenthoff50% | $105 → $105 | Reiterates | Overweight → Overweight | Get Alert |
| 06/17/2024 | Buy Now | — | Needham | Gil Blum48% | $88 → $88 | Reiterates | Buy → Buy | Get Alert |
| 05/23/2024 | Buy Now | — | Citigroup | Yigal Nochomovitz54% | $89 → $84 | Maintains | Buy | Get Alert |
| 05/10/2024 | Buy Now | — | Oppenheimer | Jay Olson61% | $102 → $95 | Maintains | Outperform | Get Alert |
| 05/09/2024 | Buy Now | — | JMP Securities | Silvan Tuerkcan44% | $86 → $86 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 05/09/2024 | Buy Now | — | Wells Fargo | Yanan Zhu36% | $70 → $65 | Maintains | Equal-Weight | Get Alert |
| 05/09/2024 | Buy Now | — | Cantor Fitzgerald | Eric Schmidt28% | — | Reiterates | → Neutral | Get Alert |
| 05/09/2024 | Buy Now | — | Barclays | Gena Wang49% | $80 → $67 | Maintains | Equal-Weight | Get Alert |
| 05/09/2024 | Buy Now | — | Needham | Gil Blum48% | $90 → $88 | Maintains | Buy | Get Alert |
| 05/09/2024 | Buy Now | — | Baird | Jack Allen 36% | $46 → $52 | Maintains | Neutral | Get Alert |
| 04/18/2024 | Buy Now | — | Citigroup | Yigal Nochomovitz54% | $88 → $89 | Maintains | Buy | Get Alert |
| 04/11/2024 | Buy Now | — | Needham | Gil Blum48% | $90 → $90 | Reiterates | Buy → Buy | Get Alert |
| 03/06/2024 | Buy Now | — | Mizuho | Salim Syed42% | $82 → $99 | Maintains | Buy | Get Alert |
| 02/26/2024 | Buy Now | — | Morgan Stanley | Terence Flynn65% | $46 → $48 | Maintains | Underweight | Get Alert |
| 02/22/2024 | Buy Now | — | RBC Capital | Luca Issi36% | $57 → $66 | Maintains | Sector Perform | Get Alert |
| 02/22/2024 | Buy Now | — | Wells Fargo | Jim Birchenough62% | $55 → $70 | Maintains | Equal-Weight | Get Alert |
| 02/22/2024 | Buy Now | — | Barclays | Gena Wang49% | $61 → $80 | Maintains | Equal-Weight | Get Alert |
| 02/22/2024 | Buy Now | — | Chardan Capital | Geulah Livshits43% | $110 → $112 | Maintains | Buy | Get Alert |
| 02/21/2024 | Buy Now | — | Needham | Gil Blum48% | $88 → $90 | Maintains | Buy | Get Alert |
| 02/15/2024 | Buy Now | — | Wolfe Research | Andy Chen32% | — | Initiates | → Peer Perform | Get Alert |
| 12/11/2023 | Buy Now | — | RBC Capital | Luca Issi36% | $50 → $57 | Maintains | Sector Perform | Get Alert |
| 12/11/2023 | Buy Now | — | Truist Securities | Joon Lee75% | $220 → $160 | Maintains | Buy | Get Alert |
| 12/11/2023 | Buy Now | — | Barclays | Gena Wang49% | $56 → $61 | Maintains | Equal-Weight | Get Alert |
| 12/11/2023 | Buy Now | — | TD Cowen | Tyler Van Buren44% | → $30 | Downgrade | Market Perform → Underperform | Get Alert |
| 12/11/2023 | Buy Now | — | JMP Securities | Silvan Tuerkcan44% | $74 → $80 | Maintains | Market Outperform | Get Alert |
| 12/11/2023 | Buy Now | — | Needham | Gil Blum48% | $85 → $88 | Maintains | Buy | Get Alert |
| 12/08/2023 | Buy Now | — | Truist Securities | Joon Lee75% | → $220 | Reiterates | Buy → Buy | Get Alert |
| 12/08/2023 | Buy Now | — | Mizuho | Salim Syed42% | → $82 | Reiterates | Buy → Buy | Get Alert |
| 12/05/2023 | Buy Now | — | JMP Securities | Silvan Tuerkcan44% | → $74 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 11/13/2023 | Buy Now | — | Morgan Stanley | Terence Flynn65% | $43 → $42 | Maintains | Underweight | Get Alert |
| 11/07/2023 | Buy Now | — | RBC Capital | Luca Issi36% | $55 → $50 | Maintains | Sector Perform | Get Alert |
| 11/07/2023 | Buy Now | — | Needham | Gil Blum48% | $88 → $85 | Maintains | Buy | Get Alert |
| 11/01/2023 | Buy Now | — | Needham | Gil Blum48% | → $88 | Reiterates | Buy → Buy | Get Alert |
| 10/30/2023 | Buy Now | — | Needham | Gil Blum48% | → $88 | Reiterates | Buy → Buy | Get Alert |
| 10/17/2023 | Buy Now | — | Cantor Fitzgerald | Eric Schmidt28% | — | Downgrade | Overweight → Neutral | Get Alert |
| 09/27/2023 | Buy Now | — | Mizuho | Salim Syed42% | → $82 | Initiates | → Buy | Get Alert |
| 08/18/2023 | Buy Now | — | Citigroup | Yigal Nochomovitz54% | → $70 | Upgrade | Neutral → Buy | Get Alert |
| 08/17/2023 | Buy Now | — | Citigroup | Yigal Nochomovitz54% | → $70 | Upgrade | Neutral → Buy | Get Alert |
| 08/14/2023 | Buy Now | — | Morgan Stanley | Terence Flynn65% | $42 → $43 | Maintains | Underweight | Get Alert |
| 08/10/2023 | Buy Now | — | Oppenheimer | Jay Olson61% | → $102 | Reiterates | Outperform → Outperform | Get Alert |
| 08/08/2023 | Buy Now | — | Credit Suisse | Richard Law42% | $62 → $63 | Maintains | Neutral | Get Alert |
| 08/08/2023 | Buy Now | — | EF Hutton | Tony Butler43% | → $75 | Reiterates | Buy → Buy | Get Alert |
| 08/08/2023 | Buy Now | — | Needham | Gil Blum48% | → $88 | Reiterates | Buy → Buy | Get Alert |
| 08/08/2023 | Buy Now | — | Chardan Capital | Geulah Livshits43% | $123 → $110 | Maintains | Buy | Get Alert |
| 07/25/2023 | Buy Now | — | JMP Securities | Silvan Tuerkcan44% | → $74 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 06/09/2023 | Buy Now | — | Needham | Gil Blum48% | $82 → $88 | Reiterates | Buy → Buy | Get Alert |
| 06/09/2023 | Buy Now | — | JMP Securities | Silvan Tuerkcan44% | $70 → $74 | Maintains | Market Outperform | Get Alert |
| 06/09/2023 | Buy Now | — | EF Hutton | Tony Butler43% | → $75 | Reiterates | → Buy | Get Alert |
| 06/01/2023 | Buy Now | — | Barclays | Gena Wang49% | $61 → $64 | Maintains | Equal-Weight | Get Alert |
| 05/30/2023 | Buy Now | — | William Blair | Sami Corwin11% | → $75 | Reinstates | → Outperform | Get Alert |
| 05/23/2023 | Buy Now | — | Citigroup | Yigal Nochomovitz54% | $55 → $70 | Maintains | Neutral | Get Alert |
| 05/12/2023 | Buy Now | — | Morgan Stanley | Terence Flynn65% | $39 → $42 | Maintains | Underweight | Get Alert |
| 05/09/2023 | Buy Now | — | RBC Capital | Luca Issi36% | → $50 | Reiterates | → Sector Perform | Get Alert |
| 05/09/2023 | Buy Now | — | JMP Securities | Silvan Tuerkcan44% | → $70 | Reiterates | → Market Outperform | Get Alert |
| 05/09/2023 | Buy Now | — | Credit Suisse | Richard Law42% | $65 → $62 | Maintains | Neutral | Get Alert |
| 05/09/2023 | Buy Now | — | Stifel | Benjamin Burnett43% | $69 → $64 | Maintains | Hold | Get Alert |
| 05/09/2023 | Buy Now | — | Needham | Gil Blum48% | → $82 | Reiterates | → Buy | Get Alert |
| 04/20/2023 | Buy Now | — | Needham | Gil Blum48% | → $82 | Reiterates | → Buy | Get Alert |
| 04/17/2023 | Buy Now | — | JMP Securities | Silvan Tuerkcan44% | → $70 | Reiterates | → Market Outperform | Get Alert |
| 04/17/2023 | Buy Now | — | EF Hutton | Tony Butler43% | → $75 | Reiterates | → Buy | Get Alert |
| 04/13/2023 | Buy Now | — | Cantor Fitzgerald | Olivia Brayer57% | → $72 | Initiates | → Overweight | Get Alert |
| 04/03/2023 | Buy Now | — | EF Hutton | Tony Butler43% | → $75 | Reiterates | → Buy | Get Alert |
| 03/21/2023 | Buy Now | — | Bernstein | William Pickering36% | → $44 | Initiates | → Market Perform | Get Alert |
| 03/18/2023 | Buy Now | — | Citigroup | Yigal Nochomovitz54% | $63 → $55 | Maintains | Neutral | Get Alert |
| 03/07/2023 | Buy Now | — | Baird | Jack Allen 36% | → $46 | Initiates | → Neutral | Get Alert |
| 02/27/2023 | Buy Now | — | JMP Securities | Silvan Tuerkcan44% | → $70 | Reiterates | → Market Outperform | Get Alert |
| 02/27/2023 | Buy Now | — | Morgan Stanley | Terence Flynn65% | $37 → $39 | Maintains | Underweight | Get Alert |
| 02/23/2023 | Buy Now | — | Oppenheimer | Jay Olson61% | $110 → $102.06 | Maintains | Outperform | Get Alert |
FAQ
What is the target price for CRISPR Therapeutics (CRSP) stock?
The latest price target for CRISPR Therapeutics (NASDAQ:CRSP) was reported by Needham on April 9, 2025. The analyst firm set a price target for $84.00 expecting CRSP to rise to within 12 months (a possible 116.05% upside). 43 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for CRISPR Therapeutics (CRSP)?
The latest analyst rating for CRISPR Therapeutics (NASDAQ:CRSP) was provided by Needham, and CRISPR Therapeutics reiterated their buy rating.
When was the last upgrade for CRISPR Therapeutics (CRSP)?
The last upgrade for CRISPR Therapeutics AG happened on February 14, 2025 when Evercore ISI Group raised their price target to $99. Evercore ISI Group previously had an in-line for CRISPR Therapeutics AG.
When was the last downgrade for CRISPR Therapeutics (CRSP)?
The last downgrade for CRISPR Therapeutics AG happened on December 11, 2023 when TD Cowen changed their price target from N/A to $30 for CRISPR Therapeutics AG.
When is the next analyst rating going to be posted or updated for CRISPR Therapeutics (CRSP)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of CRISPR Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for CRISPR Therapeutics was filed on April 9, 2025 so you should expect the next rating to be made available sometime around April 9, 2026.
Is the Analyst Rating CRISPR Therapeutics (CRSP) correct?
While ratings are subjective and will change, the latest CRISPR Therapeutics (CRSP) rating was a reiterated with a price target of $84.00 to $84.00. The current price CRISPR Therapeutics (CRSP) is trading at is $38.88, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.